Decitabine response with chromosome 7 abnormality in MDS, and decitabine optimal schedule [10]

Blood

Volumn 110, Issue 3, 2007, Pages 1083-

  Kantarjian, Hagop ^a   Huang, Xuelin ^b   Issa, Jean Pierre ^b  

^a UNIVERSITY OF TEXAS   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE;

BAYES THEOREM; CHROMOSOME 7; CHROMOSOME ABERRATION; CYTOGENETICS; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG RESPONSE; HUMAN; LETTER; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; TREATMENT DURATION;

EID: 34547942001     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2007-04-085316     Document Type: Letter

References (2)

1. Kantarjian H, O'Brien S, Shan J, et al. Update of the decitabine experience in higher risk myelodysplastic syndrome and analysis of prognostic factors associated with outcome. Cancer. 2007;109:265-273.
2. Kantarjian H, Oki Y, Garcia-Manero G, Huang X, et al. Results of a randomized study of three schedules of low-dose decitabine in higher risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood. 2007;109:52-57.